192817-79-1

Basic information

• Product Name: 2-MORPHOLIN-4-YL-BENZOIC ACID ETHYL ESTER
• Synonyms: ETHYL 2-MORPHOLIN-4-YLBENZOATE;ETHYL 2-MORPHOLINOBENZOATE;2-MORPHOLIN-4-YL-BENZOIC ACID ETHYL ESTER;RARECHEM AL BI 0462;Ethyl 2-morpholin-4-ylbenzoate 97%;Benzoic acid,2-(4-morpholinyl)-, ethyl ester
• CAS NO: 192817-79-1
• Molecular Formula: C₁₃H₁₇NO₃
• Molecular Weight: 235.28
• Product Categories: pharmacetical
• Mol File: 192817-79-1.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 369.6 °C at 760 mmHg
• Flash Point: 177.3 °C
• Appearance: /
• Density: 1.135 g/cm³
• Vapor Pressure: 1.17E-05mmHg at 25°C
• Refractive Index: 1.534
• CAS DataBase Reference: 2-MORPHOLIN-4-YL-BENZOIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 2-MORPHOLIN-4-YL-BENZOIC ACID ETHYL ESTER(192817-79-1)
• EPA Substance Registry System: 2-MORPHOLIN-4-YL-BENZOIC ACID ETHYL ESTER(192817-79-1)

Safety Data

• Hazardous Substances Data: 192817-79-1(Hazardous Substances Data)

Usage

General Description

2-MORPHOLIN-4-YL-BENZOIC ACID ETHYL ESTER is a chemical compound with the molecular formula C15H19NO4. It is an ester derivative of benzoic acid and contains a morpholine ring. 2-MORPHOLIN-4-YL-BENZOIC ACID ETHYL ESTER is commonly used in organic synthesis and pharmaceutical research as a building block in the production of various drugs and biologically active molecules. It has potential applications in the development of new therapeutic agents due to its ability to interact with biological systems. Additionally, it may also have industrial uses as a precursor in the production of other organic compounds. However, as with any chemical substance, proper handling and safety precautions should be observed when working with 2-MORPHOLIN-4-YL-BENZOIC ACID ETHYL ESTER.

InChI:InChI=1/C13H17NO3/c1-2-17-13(15)11-5-3-4-6-12(11)14-7-9-16-10-8-14/h3-6H,2,7-10H2,1H3

Upstream product

• 35244-44-1 2-morpholin-4-yl-cyclohex-1-enecarboxylic acid ethyl ester 
• 393-52-2 2-Fluorobenzoyl chloride 
• 110-91-8 morpholine 
• 6091-64-1 2-bromobenzoic acid ethyl ester 
• 534-17-8 caesium carbonate 
• 76144-87-1 2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl 
• 445-29-4 o-fluoro-benzoic acid 
• 443-26-5 2-fluoro-benzoic acid ethyl ester 

Downstream Products

• 192817-90-6 [2-(2-Morpholin-4-yl-phenyl)-2-oxo-ethyl]-phosphonic acid dimethyl ester 
• 42106-48-9 2-(morpholin-4-yl)-benzoic acid 
• 192818-05-6 dimethyl 1-diazo-2-oxo-2-(2-morpholinophenyl)ethylphosphonate 

Relevant articles and documents

Discovery of novel N-benzylbenzamide derivatives as tubulin polymerization inhibitors with potent antitumor activities

A series of novel N-benzylbenzamide derivatives were designed and synthesized as tubulin polymerization inhibitors. Among fifty-one target compounds, compound 20b exhibited significant antiproliferative activities with IC50 values ranging from 12 to 27 nM against several cancer cell lines, and possessed good plasma stability and satisfactory physicochemical properties. Mechanism studies demonstrated that 20b bound to the colchicine binding site and displayed potent anti-vascular activity. Notably, the corresponding disodium phosphate 20b-P exhibited an excellent safety profile with the LD50 value of 599.7 mg/kg (i.v. injection), meanwhile, it significantly inhibited tumor growth and decreased microvessel density in liver cancer cell H22 allograft mouse model without obvious toxicity. Collectively, 20b and 20b-P are novel promising anti-tubulin agents with more druggable properties and deserve to be further investigated for cancer therapy.

Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals

The invention relates to the use of fibrates for lowering the liver toxicity of MTP inhibitors as well as pharmaceutical compositions containing an MTP inhibitor and a fibrate.

Heteroarylcarboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions

A compound of formula wherein: Aa, Ra, X1 to X4, Het, and R5 to R7 are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, which are valuable inhibitors of the microsomal triglyceride-transfer protein (MTP), medicaments containing these compounds and their use, as well as the preparation thereof.